Obesity

Novo sues Lilly, claiming misleading ads in weight-loss drug battle

A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, in New York City, U.S., December 11, 2023 (left) and a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly, at Rock Canyon Pharmacy in Provo, Utah, U.S., March 29, 2023. REUTERS/Brendan McDermid/George Frey REFILE - QUALITY REPEAT

Study flags need to monitor frailty risks with GLP-1 drugs for older adults

Experts say the study findings do not show that the GLP-1 obesity drug Zepbound, otherwise chemically known as tirzepatide, causes adverse outcomes.

‘Spare tyre’ fat around the belly making you age faster, study says

The study found that people carrying more visceral fat tended to show signs of faster biological ageing, regardless of how much they weighed overall.

Obesity may be more prevalent than previously thought

Regardless of how they calculate it, what doctors are most concerned about is excess body fat.

Sponsored Content

Your body is fighting your diet – here’s the science that explains why

obesity treatment, weight loss challenges, metabolic health

Asian Insider

Battling the bulge jab by jab: India’s weight-loss drugs now within the reach of millions

Bengaluru-based food consultant Monika Manchanda, 50, spoke of the weight loss drug as offering a mental break from a years-long worry.

Vietnam’s weight problem grows as prosperity reshapes diets and lifestyles

Without early intervention, obesity could cost Vietnam up to US$16.28 billion (S$21 billion) by 2035, or about 2 per cent of GDP.

GLP-1 drugs may have a beneficial effect across many types of cancer

FILE PHOTO: A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams/File Photo

France to reimburse cost of weight-loss drugs for severely obese patients

Boxes of Wegovy move along a packaging line at Novo Nordisk's facility in Hillerod, Denmark, March 8, 2024. REUTERS/ Tom Little

Fatty liver genes combined with diabetes and obesity increase liver cancer risk: S’pore study

Adj A/Prof Daniel Huang, Senior Consultant, Division of Gastroenterology and Hepatology, Department of Medicine, NUH and Chair of the Hepato-Pancreato-Biliary Cancer Programme at NCIS, with his patient Mr Foo Say Nong at NUH Medical Centre on May 25, 2026.

E-paper

Newsletters

Podcasts

RSS Feed

About Us

Terms & Conditions

Personal Data Protection Notice

Need help? Reach us here.

Advertise with us

MDDI (P) 046/10/2025. Published by SPH Media Limited, Co. Regn. No.202120748H. Copyright © 2026 SPH Media Limited. All rights reserved.